Skip to main content

Table 1 Characteristics for the patients whose BM samples were tested for BiP levels in CD138+ cells

From: Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

MM code Age at diagnosis Ouant Immunoglobulins and Serum immunofixation at collection Albumin LDH Prior Bortezomib? Myeloma status at time of Collection
MM16 64 lgG 2371, monoclonal protein in gamma region 4.3 201 no Stable disease
MM17 59 IgG 282, IgA 5083, IgM 16, Two IgA lambda monoclonal band seen, representing 85 % 3.7 106 yes Stable disease
MM18 68 IgG 2333, IgA 12, 1gM 20, monoclonal protein seen in gamma region 3.3 175 yes Progression of Disease (increase in M-spike)
MM19 46 IgG 4656, IgA 27, 1 gM 53, monoclonal protein in gamma region 3.8 142 no Minimal response/stable disease
MM20 unav IgG 4099, monoclonal band in gamma region 3.7 121 unav Stable Disease
MM21 56 IgG 314, 1 gM <5, IgA <5, faint free kappa band 4.7 143 yes Progression of Disease
MM22 52 IgG 453, 1 gM 7, IgA 132, faint IgG lambda band 2.7 170 yes partial response/stable disease
MM23 70 lgG 840, IgA 9, 1 gM 9, lgG kappa monoclonal spike seen, representing all of monoclonal protein 4.5 564 yes Remission (very good partial response)
MM24 57 lgG 255, 1 gM 12, IgA 19, faint free Lambda band seen 3.1 154 yes Progression of Disease
MM25 39 lgG 188, IgA 10, 1gM 12, Free monoclonal lambda light chain, normal Igs greatly diminished 4.7 601 yes Progression of Disease
MM26 66 lgG 6589, Iga 8, 1 gM <5, lgG kappa monoclonal representing all of total 3.9 166 yes Progression of Disease
MM27 54 lgG 5543, IgA 11, 1 gM 19, lgG kappa monoclonal protein 4.1 210 yes Progression of Disease